Its label limits it to people with a body mass index of 30 or more, or 27 or more with another risk factor such as controlled high blood pressure, diabetes or high cholesterol, alongside exercise, behavior change and fewer calories. It is a schedule IV controlled substance and is not a GLP-1 medicine. It is also one of the two ingredients of Qsymia.1,2
What it is
The label calls phentermine a sympathomimetic amine whose activity is similar to amphetamine, and it groups it with the drugs commonly known as anorectics. It also says something unusual for a label: it has not been established that these drugs work mainly by suppressing appetite, since other effects on the brain or metabolism may be involved.1 MedlinePlus puts it more simply: phentermine works by decreasing appetite.3
How it is used
Phentermine comes as tablets and extended-release capsules, taken once a day in the morning or up to three times a day about 30 minutes before meals. MedlinePlus says most people take it for 3 to 6 weeks.3 The 8 mg Lomaira tablet, for example, is taken up to three times a day half an hour before meals, and late-evening doses are avoided because of insomnia. The label does not recommend it for anyone 16 or younger.1
The label adds a rule about tolerance. If the appetite effect fades, the dose is not to be raised to get it back; the drug is to be stopped instead.1
How much it does
The phentermine label is frank about the size of the effect. In the studies of drugs of this class, the extra weight lost on the drug over placebo was only a fraction of a pound a week. Weight loss was greatest in the first weeks on both drug and placebo and slowed afterwards, and the label asks prescribers to weigh this limited usefulness against the risks.1
In Qsymia, phentermine is combined with topiramate in one daily capsule approved for long-term use. At the top dose of 15 mg/92 mg, adults with obesity lost 10.9% of their weight in a year, against 5.1% on the low dose of 3.75 mg/23 mg and 1.6% on placebo.2 On Wegovy 2.4 mg, adults lost 14.9% over 68 weeks in a separate trial, against 2.4% on placebo.4
Risks and who should not take it
The label rules phentermine out for people with a history of heart disease, including coronary artery disease, stroke, irregular heart rhythms, heart failure or uncontrolled high blood pressure. It is also ruled out with an overactive thyroid, glaucoma, agitated states, a history of drug abuse, pregnancy and breastfeeding, and within 14 days of a monoamine oxidase inhibitor.1
Two rare but serious conditions are on the label. Primary pulmonary hypertension, a rare and often fatal lung disease, and damage to the heart valves were reported in people who took phentermine together with fenfluramine or dexfenfluramine. A link to phentermine alone cannot be ruled out; rare cases of pulmonary hypertension have been reported with it. Shortness of breath is usually the first symptom.1
Because it is related to amphetamine, the label asks prescribers to keep the possibility of abuse in mind, and it lists withdrawal effects after prolonged high doses. It may also impair the ability to drive or operate machinery.1
Phentermine next to a GLP-1
| Question | Phentermine alone | Wegovy or Zepbound |
|---|---|---|
| How long | A few weeks | Long term |
| Form | Tablet or capsule, daily | Weekly injection |
| Controlled substance | Schedule IV | No |
| Heart disease | Ruled out | Wegovy lowers heart risk |
LOMAIRA, WEGOVY and ZEPBOUND labels.1,4
Sources
- LOMAIRA (phentermine hydrochloride) tablets prescribing information. DailyMed, U.S. National Library of Medicine, version published June 1, 2026; indications, contraindications, warnings, dosage, drug abuse and dependence, and clinical pharmacology. dailymed.nlm.nih.gov
- QSYMIA (phentermine and topiramate extended-release capsules) prescribing information. Vivus LLC; DailyMed, version published April 24, 2026; sections 1 and 14. dailymed.nlm.nih.gov
- MedlinePlus. Phentermine. U.S. National Library of Medicine; last revised December 15, 2024, read November 20, 2026. medlineplus.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026, sections 1 and 14; and ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026, section 1. U.S. Food and Drug Administration. accessdata.fda.gov
Related analyses
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Wegovy weight loss chart: the trial results week by week, in your own weight
Zepbound plateau: when weight loss slows, why, and what the trials show
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Log your medicines, weight and symptoms together in one place.
Open Dose Insider